Suppliers and packagers for METHOXSALEN

METHOXSALEN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Onesource Specialty	METHOXSALEN	methoxsalen	CAPSULE;ORAL	202687	ANDA	Strides Pharma Science Limited	64380-752-16	50 CAPSULE, LIQUID FILLED in 1 BOTTLE, GLASS (64380-752-16)	2016-12-08

Methoxsalen Drug Supply Chain Analysis

Last updated: February 19, 2026

Methoxsalen, a psoralen compound, is used to treat psoriasis, eczema, and vitiligo. Its synthesis and supply chain involve specialized chemical manufacturers. Key suppliers are identified by their chemical synthesis capabilities, regulatory compliance, and capacity to produce active pharmaceutical ingredients (APIs) and intermediates under Good Manufacturing Practices (GMP).

What are the Primary Chemical Precursors for Methoxsalen Synthesis?

The synthesis of methoxsalen (8-methoxypsoralen) typically originates from furanocoumarin structures. A common synthetic route involves intermediates derived from resorcinol or related phenolic compounds. Specific precursors can include:

• Resorcinol: A foundational aromatic organic compound.
• Acetoacetic ester or similar beta-keto esters: Used in condensation reactions.
• Haloacetates or related alkylating agents: To introduce alkyl chains.
• Formylating agents: For introducing aldehyde functionalities.
• Oxidizing agents: For cyclization and functional group transformations.

The precise sequence and specific reagents vary depending on the patented synthetic route employed by manufacturers. For example, one common pathway involves the Pechmann condensation followed by Vilsmeier-Haack formylation and subsequent cyclization steps.

Who are the Key Suppliers of Methoxsalen API and Intermediates?

Identifying specific API manufacturers for methoxsalen requires direct engagement with the pharmaceutical supply chain. However, based on general industry capabilities in psoralen and furanocoumarin synthesis, the following types of suppliers are likely involved:

• Specialty Chemical Manufacturers: Companies with expertise in heterocyclic chemistry and the production of complex organic molecules.
• Contract Development and Manufacturing Organizations (CDMOs): These organizations provide custom synthesis services and can scale up production for APIs and intermediates.
• Manufacturers of Psoralen Derivatives: Companies that already produce related compounds may have the infrastructure and expertise to manufacture methoxsalen.

While public databases do not always list specific APIs manufactured by individual companies for competitive reasons, regions with strong fine chemical industries, such as China, India, and parts of Europe, are primary sourcing locations. Companies specializing in APIs for dermatological and photochemotherapy applications are also potential suppliers.

What Regulatory Standards Govern Methoxsalen Production?

The production of methoxsalen as an API must adhere to stringent regulatory standards to ensure safety, efficacy, and quality. These standards are enforced by global health authorities.

• Good Manufacturing Practices (GMP): Mandated by agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). GMP ensures that products are consistently produced and controlled according to quality standards. This includes detailed requirements for facilities, equipment, personnel, documentation, and quality control.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines on quality, safety, and efficacy. For API manufacturing, ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) is particularly relevant.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory bodies to review the API information without the manufacturer disclosing proprietary details to the drug product applicant.
• Pharmacopoeial Standards: Methoxsalen must meet specifications outlined in pharmacopoeias such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These monographs define identity, purity, assay, and other quality attributes.

Compliance is verified through regular inspections by regulatory bodies and customer audits. Any deviation from these standards can lead to production halts, product recalls, and severe market access restrictions.

What are the Key Considerations for Securing a Reliable Methoxsalen Supply?

Securing a consistent and high-quality supply of methoxsalen involves a multi-faceted approach focused on supplier vetting, risk mitigation, and quality assurance.

• Supplier Qualification:
  • GMP Compliance Verification: Rigorous audits of manufacturing sites to confirm adherence to GMP. This includes reviewing quality management systems, validation processes, and change control procedures.
  • Regulatory Track Record: Assessment of the supplier's history with regulatory agencies, including any past enforcement actions or deficiencies.
  • Technical Capabilities: Evaluation of the supplier's synthetic expertise, analytical capabilities, and experience with the specific chemistry of methoxsalen.
  • Financial Stability: Assessment of the supplier's financial health to ensure long-term viability and commitment.
• Supply Chain Risk Management:
  • Dual Sourcing: Establishing relationships with at least two qualified suppliers to mitigate the risk of single-source dependency. This is critical for critical raw materials and APIs.
  • Geographic Diversification: Sourcing from suppliers in different geographic regions to reduce exposure to localized disruptions (e.g., natural disasters, political instability, trade restrictions).
  • Inventory Management: Maintaining adequate safety stock levels for both API and key intermediates to buffer against unexpected supply interruptions. This requires careful forecasting and collaboration with suppliers.
  • Contingency Planning: Developing and documenting contingency plans for potential disruptions, including alternative suppliers, transportation routes, and production sites.
• Quality Assurance and Control:
  • Incoming Material Testing: Implementing robust testing protocols for all incoming batches of methoxsalen API and critical intermediates to confirm they meet specifications.
  • Change Control Management: Establishing a formal process for evaluating and approving any changes to a supplier's manufacturing process, materials, or facilities that could impact product quality.
  • Regular Audits: Conducting periodic audits of suppliers to ensure ongoing compliance and identify any emerging risks.
  • Certificate of Analysis (CoA) Review: Thoroughly reviewing CoAs for each batch to ensure all parameters are within specified limits.

These measures are essential for pharmaceutical companies to maintain product quality, ensure patient safety, and meet market demand.

What are the Patent Landscape and Exclusivity Considerations for Methoxsalen?

The patent landscape for methoxsalen is complex, involving patents related to its synthesis, formulations, and therapeutic uses. As methoxsalen has been in use for decades, the original composition of matter patents have long expired. However, new intellectual property can still be generated.

• Composition of Matter Patents: The original patents covering the methoxsalen molecule itself have expired. These typically have a lifespan of 20 years from the filing date.
• Process Patents: Patents can be granted for novel or significantly improved methods of synthesizing methoxsalen. These patents protect specific synthetic routes, purification techniques, or polymorphic forms. For example, a patent might claim a more efficient, cost-effective, or environmentally friendly manufacturing process.
• Formulation Patents: Patents may cover specific pharmaceutical formulations of methoxsalen, such as topical solutions, oral capsules, or delayed-release preparations, which aim to improve delivery, efficacy, or patient compliance.
• Method of Use Patents: Patents can be obtained for new therapeutic applications of methoxsalen or for specific treatment protocols using methoxsalen in combination with other therapies (e.g., photochemotherapy regimens).
• Exclusivity Periods:
  • Data Exclusivity: Regulatory agencies can grant periods of market exclusivity for certain drugs, independent of patent protection. For example, in the U.S., New Chemical Entities (NCEs) can receive 5 years of data exclusivity, while certain other categories may receive shorter periods.
  • Orphan Drug Exclusivity: If methoxsalen is designated as an orphan drug for a rare disease, it can receive 7 years of market exclusivity in the U.S. and 10 years in the EU.
  • Patent Term Extension: In some jurisdictions, patent terms can be extended to compensate for regulatory delays encountered during drug development and approval.

Understanding the active patents and exclusivity periods is critical for generic manufacturers seeking to enter the market and for innovator companies looking to protect their ongoing investments in methoxsalen-based therapies. It dictates market entry timelines and potential infringement risks.

How is Methoxsalen Packaged and Stored?

The packaging and storage of methoxsalen are crucial for maintaining its stability and potency, given its sensitivity to light and potential for degradation.

• Packaging:
  • Light-Resistant Containers: Methoxsalen is highly photosensitive. Therefore, it is typically packaged in amber glass bottles or opaque, light-blocking containers.
  • Inert Atmosphere: Packaging may occur under an inert atmosphere, such as nitrogen, to prevent oxidative degradation.
  • Child-Resistant Closures: For finished drug products, child-resistant packaging is mandated in many regions.
  • Material Compatibility: Packaging materials must be inert and not react with methoxsalen or its excipients.
• Storage Conditions:
  • Temperature Control: Recommended storage temperatures are typically at controlled room temperature (e.g., 20°C to 25°C or 68°F to 77°F), but specific requirements can vary based on the formulation and manufacturer's stability data. Refrigeration may be required for certain liquid formulations.
  • Protection from Light: Storage must always be in a dark place, away from direct sunlight or artificial light sources. This is paramount.
  • Humidity Control: Storage areas should be dry to prevent moisture ingress, which can lead to degradation or microbial growth in formulations.
  • Segregation: Methoxsalen should be stored separately from incompatible materials.

Manufacturers provide specific storage instructions on product labels and in their package inserts, which must be followed meticulously by distributors, pharmacists, and patients.

Key Takeaways

• Methoxsalen synthesis relies on specialized organic chemistry, originating from precursors like resorcinol, with multiple synthetic routes possible.
• Key suppliers are specialty chemical manufacturers and CDMOs with expertise in GMP-compliant API production, often located in regions with robust fine chemical industries.
• Production is strictly governed by GMP, ICH guidelines, and pharmacopoeial standards, with DMFs serving as critical regulatory filings.
• Securing a reliable supply chain necessitates rigorous supplier qualification, dual sourcing, geographic diversification, and robust quality assurance protocols.
• While original composition of matter patents have expired, patents for novel synthesis processes, formulations, and uses continue to shape the market landscape.
• Packaging and storage must prioritize light protection and controlled environmental conditions to maintain methoxsalen's stability and efficacy.

Frequently Asked Questions

1. What is the typical shelf life of methoxsalen API when stored correctly? API shelf life varies by manufacturer and specific product characteristics, but a typical shelf life for well-characterized APIs under controlled conditions can range from 2 to 5 years. Specific stability studies and dating from the manufacturer are definitive.

2. Are there any significant environmental considerations in methoxsalen manufacturing? Yes, the synthesis of complex organic molecules like methoxsalen often involves solvents, reagents, and byproducts that require careful handling, waste treatment, and disposal to meet environmental regulations. Process optimization can minimize waste generation.

3. How does the phototoxicity of methoxsalen impact its supply chain logistics? The inherent phototoxicity of methoxsalen necessitates special handling and packaging throughout the supply chain, from manufacturing to warehousing and transportation, to prevent degradation and ensure product integrity before it reaches the end-user.

4. Can methoxsalen API be sourced from a single supplier with assurance? While possible, relying on a single supplier for critical APIs like methoxsalen poses significant risk. Pharmaceutical companies typically aim for dual or multi-sourcing strategies to ensure continuity of supply and mitigate risks associated with one supplier's production issues, regulatory actions, or business disruptions.

5. What is the role of micronization in methoxsalen API production? Micronization, a process that reduces particle size, can be important for APIs to improve dissolution rates and bioavailability in certain drug formulations, particularly for oral or topical applications. The need for micronization depends on the specific formulation requirements for methoxsalen.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [FDA Website] (Specific URL omitted as it is a dynamic site.)

[2] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from [ICH Website] (Specific URL omitted as it is a dynamic site.)

[3] United States Pharmacopeia. (n.d.). USP <1072> Disinfectants and Sterilants. Retrieved from [USP Website] (Specific URL omitted as it is a dynamic site. This relates to general quality standards, not a specific methoxsalen monograph.)

[4] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA Website] (Specific URL omitted as it is a dynamic site.)